Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.40
-1.6%
$2.16
$0.95
$2.85
$21.90M0.13147,409 shs86,793 shs
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.03
-4.2%
$1.20
$0.87
$2.55
$20.18M0.52129,046 shs106,220 shs
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$9.72
-13.3%
$9.94
$3.08
$597.60
$15.40M0.075.39 million shs145,070 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.39
-1.6%
$2.81
$1.72
$15.70
$4.87M0.29147,390 shs50,579 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-1.64%-8.75%+4.80%+83.22%-9.43%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-4.21%-5.96%-10.87%-27.82%-12.39%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-13.29%-39.40%+161.40%-83.88%-97.59%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-1.65%-9.47%-21.64%-22.65%-32.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.1736 of 5 stars
3.52.00.03.40.60.00.6
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2.9335 of 5 stars
3.53.00.00.03.31.70.6
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.2531 of 5 stars
0.02.00.00.01.11.70.0
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.0996 of 5 stars
0.02.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.00
Buy$10.00316.67% Upside
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50729.27% Upside
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.00
HoldN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INM, CMMB, AYTU, and CYCC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
6/30/2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
5/16/2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$81M0.27N/AN/A$4.64 per share0.52
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$14K1,100.44N/AN/A($58.87) per share-0.17
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.60M1.04N/AN/A$20.64 per share0.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$15.84M-$0.72N/AN/A2.37%3.51%0.91%9/25/2025 (Estimated)
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$11.21M-$839.58N/AN/AN/A-3,648.09%-155.99%8/13/2025 (Estimated)
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$12.09N/AN/A-168.87%-107.93%-82.97%9/29/2025 (Estimated)

Latest INM, CMMB, AYTU, and CYCC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/20/2025Q2 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/14/2025Q3 2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million
5/12/2025Q3 2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$1.94N/A-$1.94N/A$1.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$0.151.54%N/AN/A N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.27
1.03
0.87
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
5.33
5.33
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
5.60
5.60
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
3.49
3.04

Institutional Ownership

CompanyInstitutional Ownership
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
33.49%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
46.05%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
1608.98 million8.65 millionNot Optionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2018.86 million16.61 millionNot Optionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
141.59 million773,000Optionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
102.00 million1.97 millionNot Optionable

Recent News About These Companies

InMed Pharmaceuticals Secures $5M in Private Placement
InMed Pharmaceuticals announces INM-089 IVT formulation as drug candidate

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$2.40 -0.04 (-1.64%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.40 0.00 (-0.21%)
As of 08/1/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.02 -0.05 (-4.21%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$1.03 +0.01 (+0.98%)
As of 08/1/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Cyclacel Pharmaceuticals stock logo

Cyclacel Pharmaceuticals NASDAQ:CYCC

$9.72 -1.49 (-13.29%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$9.60 -0.12 (-1.23%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$2.39 -0.04 (-1.65%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.37 -0.02 (-0.84%)
As of 08/1/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.